From "contraindicated" to "first line" - Current mechanistic insights beyond canonical β-receptor signaling
Curr Opin Pharmacol. 2024 Apr 17;76:102458. doi: 10.1016/j.coph.2024.102458. Online ahead of print.ABSTRACTβ-blockers are a solid pillar in the treatment of cardiovascular diseases. However, they are highly discussed regarding effectiveness for certain indications and side-effects. Even though there are up to 20 licensed compounds, only four are used for heart failure (HF) therapy. On the receptor level several key characteristics seem to influence the clinical outcome: subtype selectivity, antagonistic vs (inverse/biased) agonistic properties and -in particular- ancillary capacities. On a molecular level, divergent and n...
Source: Current Opinion in Pharmacology - April 18, 2024 Category: Drugs & Pharmacology Authors: Theresa Brand Ann-Kathrin Lukannek Val érie Jahns Roland Jahns Kristina Lorenz Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
